<DOC>
	<DOCNO>NCT01973751</DOCNO>
	<brief_summary>Novel asthma biomarkers predict response inhale corticosteroid Brief description : This single center study asthmatic subject healthy control investigate mechanism underlie different response inhale corticosteroid , mainstay asthma therapy . Only half asthmatic patient improve lung function treatment inhale corticosteroid . The investigator hypothesize biomarkers epithelial cytokine ( IL-25 , IL-33 , TSLP ) airway tissue plasma asthmatic patient could predict response asthmatic patient inhale corticosteroid . Finding novel asthma biomarker help clinician choose optimal treatment individual asthmatic patient .</brief_summary>
	<brief_title>Asthma Biomarkers Predicting Response Therapy</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Group A : Male female subject age 18 70 year No respiratory symptom Normal spirometric value methacholine PD20 &gt; 2.5mg Group B : Male female subject age 18 70 year History asthma No use oral inhale corticosteroid treatment asthma No use leukotriene antagonist treatment asthma Hyperreactivity methacholine ( PD20 FEV1 Methacholine &lt; 2.5 mg ) and/or ≥12 % increase FEV1 follow inhalation 200μg salbutamol Asthma symptom episodic cough , wheeze and/or breathlessness Current former smoker Pregnant woman Subjects history lung disease asthma Subjects history medical disease , opinion investigator may put subject extra risk studyrelated procedure disease may influence result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>